A new gene therapy, Celosia's CTx1000, is now being tested for ALS in a small clinical trial in Australia. The one-time treatment targets toxic TDP-43 protein clumps, a key driver of most cases of ALS ...

That attitude may have served me then, but since my ALS diagnosis, I’ve had to adopt a new, more balanced way of thinking.

The ALS therapy candidate AP-101 significantly extended patient survival and delayed the need for respiratory support in a ...

PET tracer ACI-19626 safely detects toxic TDP-43 protein clumps in the brain. TDP-43 clumps are a hallmark in 97% of ALS ...

Early PrimeC treatment slowed functional decline and reduced the risk of death or ALS complications for ALS patients in a ...

A brain implant helps paralyzed patients type on a computer by decoding attempted finger movements. The device enables rapid, ...

Eye imaging may help distinguish ALS from Alzheimer’s disease by revealing differences in retinal protein deposits using polarized light.

The funding is part of the expanding ALS Research Innovation Initiative. It’s intended to support “bold” and “imaginative” projects that could address key problems in ALS using innovative technologies ...

When it comes to constantly adapting to the progression of her husband's ALS, columnist Kristin Neva is both an "old-timer" ...

Acurastem received a grant to develop ALS therapies targeting SYF2, a regulator of TDP-43, in collaboration with academic ...

Asking for help or giving instructions can feel intimidating, but being pushy helps ensure patients' well-being, says ...

Amydis has received $2.5 million to continue mapping toxic deposits of TDP-43 in retinal tissue and develop an eye test for ...